EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieValidierungsstudieOpen Access · CC BY 4.0

LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients

Valentina Franco, Michela Palmisani iD, Fabiana Colucci iD, Rosa De Micco, Simone Aloisio iD, Federico Cazzaniga, Silvia Cerri iD, Francesca Crema, Francesca Dattrino iD, Barbara Garavaglia iD, Matteo Gastaldi, Pierfrancesco Mitrotti iD und 9 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136094 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Valentina Franco und 20 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Ambroxol, Glucosylceramidase, Parkinson Disease, Tandem Mass Spectrometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of Health granted to IRCCS Mondino Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterozygous mutations in the GBA1 gene, encoding the enzyme glucocerebrosidase (GCase), are major risk factors for Parkinson’s Disease (PD). Ambroxol, a small chaperone originally used as a mucolytic agent, has been shown to cross the blood–brain barrier, enhance GCase activity, and reduce α-synuclein levels, making it a promising therapeutic candidate for disease-modifying effects in GBA1-associated PD (GBA1-PD). This study aimed to develop a method to quantify ambroxol levels in human plasma and cerebrospinal fluid (CSF) using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Ambroxol was determined by online solid-phase extraction (SPE), coupled with LC-MS/MS, by gradient elution on a monolithic column. Detection employed a 3200 QTRAP tandem mass spectrometer in the positive electrospray ionization mode. Calibration curves exhibited linearity across the analyzed ranges in both plasma and CSF. The recovery rate ranged from 106.7% to 113.5% in plasma and from 99.0% to 103.0% in CSF. No significant matrix effect was observed. Intra-day and inter-day precisions were below 11.8% in both matrices, and accuracy ranged from 89.9% to 103.1% in plasma and from 96.3% to 107.8% in CSF. We evaluated and confirmed the stability of the analyte in plasma and CSF across various storage conditions. The method was successfully validated according to European Medicine Agency (EMA) guidelines and its applicability was confirmed in the context of a multicenter, randomized, double-blind, placebo-controlled, phase II study, designed to monitor the ambroxol levels in the plasma and CSF of GBA1-PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmbroxolGlucosylceramidaseParkinson DiseaseTandem Mass SpectrometryAgedFemaleHumansMaleMiddle AgedChromatography, LiquidLiquid Chromatography-Mass SpectrometrySolid Phase Extraction

Stichwörter der Autor:innen

LC-MS/MSParkinson’s Diseaseambroxolcerebrospinal fluidglucocerebrosidaseplasma

Substanzen

AmbroxolGBA protein, humanGlucosylceramidase

Autor:innen und Institutionen

  • Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy.
  • IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Parkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy.
  • Department of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, Italy.
  • Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
  • Laboratory of Clinical Pathology, Unit of Laboratory Medicine, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy.

ORCID-Profile: Michela Palmisani, Fabiana Colucci, Simone Aloisio, Silvia Cerri, Francesca Dattrino, Barbara Garavaglia, Pierfrancesco Mitrotti, Fabio Moda, Paola Rota, Rita Stiuso, Cristina Tassorelli, Roberto Eleopra, Enza Maria Valente, Micol Avenali

Förderung

  • Italian Ministry of Health
  • Italian Ministry of Health granted to IRCCS Mondino Foundation

Zitieren

APA

Franco, V., Palmisani, M., Colucci, F., De Micco, R., Aloisio, S., Cazzaniga, F., Cerri, S., Crema, F., Dattrino, F., Garavaglia, B., Gastaldi, M., Mitrotti, P., Moda, F., Rota, P., Stiuso, R., Tassorelli, C., Eleopra, R., Tessitore, A., Valente, E. M., …, & Cilia, R. (2025). LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136094

Vancouver

Franco V, Palmisani M, Colucci F, De Micco R, Aloisio S, Cazzaniga F, et al. LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136094

BibTeX
@article{Franco2025,
  author = {Franco, Valentina and Palmisani, Michela and Colucci, Fabiana and De Micco, Rosa and Aloisio, Simone and Cazzaniga, Federico and Cerri, Silvia and Crema, Francesca and Dattrino, Francesca and Garavaglia, Barbara and Gastaldi, Matteo and Mitrotti, Pierfrancesco and Moda, Fabio and Rota, Paola and Stiuso, Rita and Tassorelli, Cristina and Eleopra, Roberto and Tessitore, Alessandro and Valente, Enza Maria and Avenali, Micol and Cilia, Roberto},
  title = {LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136094}
}
Kostenlos starten →